Skip to main content

Day: August 12, 2021

CENAQ Energy Corp. Announces Pricing of $150 Million Initial Public Offering

Houston, TX, Aug. 12, 2021 (GLOBE NEWSWIRE) — CENAQ Energy Corp. (the “Company”) announced today the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. The units will be listed on the NASDAQ Stock Market, LLC (“NASDAQ”) and will trade under the ticker symbol “CENQU” beginning on August 13, 2021.  Each unit issued in the offering consists of one share of the Company’s Class A common stock and three-quarters of one warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at an exercise price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on NASDAQ under the symbols “CENQ” and “CENQW,” respectively. No fractional warrants will be issued...

Continue reading

Pacific Health Care Organization, Inc. Reports its 2021 Second Quarter Results

Newport Beach, CA, Aug. 12, 2021 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its quarterly report on Form 10-Q announcing financial results for the quarter ended June 30, 2021. Quarterly Results The Company reported net income of $94,711, or $0.01 per basic and fully diluted common share for the three months ended June 30, 2021, compared to net income of $106,589, or $0.01 per basic and fully diluted common share for the three months ended June 30, 2020.   For the first six months of 2021 the Company reported net income of $601,996 or $0.05 per basic and fully diluted common share, compared to net income of $229,717 or $0.02 per basic and fully diluted common share for the first six months of 2020. Total revenues...

Continue reading

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021

BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright Ophthalmology Virtual Conference as follows:Date: Tuesday, August 17, 2021Time: On DemandWebcast: https://journey.ct.events/view/b4009ee7-d4bf-41a2-b263-30a028b27c98The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section. About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development...

Continue reading

NXT Energy Solutions Announces Second Quarter 2021 Results

CALGARY, Alberta, Aug. 12, 2021 (GLOBE NEWSWIRE) — NXT Energy Solutions Inc. (“NXT” or the “Company”) (TSX: SFD; OTC QB: NSFDF) today announced the Company’s financial and operating results for the quarter ended June 30, 2021. All dollar amounts herein are in Canadian Dollars unless otherwise identified. Q2 Financial and Operating Highlights Key financial and operational highlights for Q2-21 are summarized below:The Company recorded survey revenue of $3.14 million in Q2-21 and YTD 2021; Net income per common share for Q2-21 was $0.02 basic and $0.02 diluted, including stock-based compensation and amortization expense of $0.50 million; Cash flow provided by operating activities was $0.73 million during Q2-21; Net income per common share for YTD 2021 was $0.00 basic and $0.00 diluted, including stock-based...

Continue reading

GINSMS Announces Financial Results for the Three and Six Months Ended June 30, 2021

CALGARY, Alberta, Aug. 12, 2021 (GLOBE NEWSWIRE) — GINSMS Inc. (TSXV: GOK) (the “Corporation”) has announced its financial results for the second quarter ended June 30, 2021. The complete financial results for GINSMS are available at www.sedar.com. Highlights include:Revenue of $760,489 for the three-month period ended June 30, 2021 as compared to $647,536 for the three-month period ended June 30, 2020. Gross Profit of $262,760 for the three-month period ended June 30, 2021 as compared to gross profit of $207,140 for the three-month period ended June 30, 2020. Operating expenses and finance costs increased from $107,882 for the three-month period ended June 30, 2020 to $142,431 for the three-month period ended June 30, 2021. Net profit of $120,329 for three-month period ended June 30, 2021 as compared to a net profit of $99,014...

Continue reading

Maui Land & Pineapple Reports 2nd Quarter 2021 Results

KAPALUA RESORT, Hawaii, Aug. 12, 2021 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) reported net income of $1.9 million, or $0.10 per share, for the second quarter of 2021, compared to a net loss of $0.2 million, or $(0.01) per share, for the second quarter of 2020. Total operating revenues of $5.0 million and $1.7 million were recognized during the three months ended June 30, 2021 and 2020, respectively. For the six months ended June 30, 2021, the Company reported net income of $0.9 million, or $0.05 per share, compared to a net loss of $1.2 million, or $(0.06) per share, for the six months ended June 30, 2020. Total operating revenues of $7.0 million and $3.7 million were recognized during the six months ended June 30, 2021 and 2020, respectively. During the quarter ended June 30, 2021, MLP completed...

Continue reading

Diversified Royalty Corp. Announces Second Quarter 2021 Results and Appointment of New Independent Director

VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months ended June 30, 2021 (“Q2 2021”) and six months ended June 30, 2021. HighlightsRevenue of $9.2 million in Q2 2021 and $16.8 million for the six months ended June 30, 2021, up 45.8% compared to the three months ended June 30, 2020 (“Q2 2020”) and 23.8% compared to the six months ended June 30, 2020Adjusted revenue of $10.4 million in Q2 2021 and $19.2 million for the six months ended June 30, 2021, up 38.7% and 20.5%, respectively, compared to the same periods in 2020Distributable cash of $6.8 million in Q2 2021 and $12.7 million for the six months ended June 30, 2021, up 38.3% and 22.0%, respectively, compared to the same...

Continue reading

CAPREIT Reports Continued Growth and Strong Operating Performance in Second Quarter of 2021

TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today continuing strong operating and financial results for the three and six months ended June 30, 2021. HIGHLIGHTS:  Three Months Ended Six Months Ended  June 30, June 30,  2021 2020 2021 2020 (5)Portfolio Performance        Overall portfolio occupancy (1)     97.2 % 98.0  %Overall portfolio net Average Monthly Rents (1) (2)     $ 1,118   $ 1,104   Operating revenues (000s) $ 228,856   $ 219,925   $ 456,362   $ 435,985  Net rental income (“NOI”) (000s) $ 151,786   $ 143,233   $ 298,438   $ 281,291  NOI Margin 66.3 % 65.1 % 65.4 % 64.5 %         Financial Performance        Normalized Funds from Operations (“NFFO”) (000s)...

Continue reading

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have an unmet medical need condition, announces today financial results for the quarter ended June 30, 2021, and provides corporate update. Dr. David Young, CEO and chairman of Processa, commented, “During the second quarter we made significant progress advancing our clinical programs, in-licensed another clinical asset – RX-3117 – and will have four clinical programs with addressable markets of $500 million to $1.5 billion. Looking at upcoming milestones, we have begun to develop the biomarker assays for 3117 in pancreatic...

Continue reading

ConnectOne Bancorp, Inc. Announces Pricing of Depositary Shares Offering

ENGLEWOOD CLIFFS, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (NASDAQ: “CNOB”), (the “Company”), the holding company for ConnectOne Bank (the “Bank”), announced today that it has priced a public offering of 4,000,000 depositary shares with a liquidation preference of $25.00 per share (the “Depositary Shares”), for gross proceeds of $100,000,000 before deducting underwriting discounts and other estimated offering expenses. Each Depositary Share represents a 1/40th interest in a share of the Company’s 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. In connection with the offering, the Company has granted the underwriters an option for 30 days to purchase up to an additional 600,000 Depositary Shares. The Company intends to list the Depositary Shares on The Nasdaq Global...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.